Cordis and Medinol Announce FDA Approval of the Innovative EluNIR Drug-Eluting Stent System

EluNIR is shown to effectively treat highly complex disease with optimized stent and delivery system DUBLIN, Ohio, Nov. 30, 2017 -- (Healthcare Sales & Marketing Network) -- Cordis, a Cardinal Health company, and Medinol today announced United States F... Devices, Interventional, Cardiology, FDA Cordis, Cardinal Health, Medinol, EluNIR, drug-eluting stent
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news